- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Champions Biotechnology, Inc. (OTCBulletinBoard: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Do-Coop Technologies Ltd. of Israel for development of a more soluble form of SG410, its Benzoylphenylurea (BPU) sulfur analog compound. SG410, an in-licensed compound, is the first agent in Champions' drug development pipeline. Using Neowater((R)), a novel proprietary water-based nanotechnology, Do-Coop has been able to improve the solubility and activity of SG410.
SG410 is an antimitotic inhibitor that was shown in Biomerk Tumorgraft models to target microtubule associated protein tau (MAPT) deficient tumors with promising results as compared to a currently marketed and leading chemotherapeutic drug. These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau) deficient tumors. In both in vitro and in vivo models, SG410 has demonstrated promising activity against prostate and pancreatic cancer.
"We are excited to work with this innovative technology that enables us to move SG410 into Biomerk Tumorgraft testing and determine its optimal clinical application," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "We expect to have early Biomerk Tumorgraft results for SG410 by the end of 2009. Also, following nearly a year of efforts to build our oncology drug pipeline we expect to in-license additional drugs in the near future; SG410 is anticipated to be the first of many in-licensed compounds to enter Biomerk Tumorgraft evaluation. Our Biomerk Tumorgraft technology enables identification of the most promising development path for the compound in terms of indication, drug combination, and target patient populations. Studies suggest that evaluations of compounds through Biomerk Tumorgrafts will lead to more efficient and successful clinical development."
Under the terms of the agreement, Do-Coop will receive development milestones and royalties based upon the clinical success of the compound. "We are delighted to work with Champions and its groundbreaking Biomerk Tumorgraft platform," said Eran Gabbai, President and CTO of Do-Coop. "This technology should change the way in which cancer drugs are developed."
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.
About Do-Coop Technologies Ltd.
Do-Coop Technologies Ltd. specializing in manufacturing and commercialization of its own novel and proprietary water-based nanotechnology, branded as Neowater((R)). Neowater((R)) displays a clear shift in water known physical properties due to the unique organization and interaction between water, suspended nanoparticles and carbon dioxide. Do-Coop focuses its effort in improving Pharmaceutical and Bio-Pharma applications within the life science industry. Due to its novelty, Neowater((R)) can be utilized in various applications. Neowater((R)) offers better bioavailability, efficacy, stability, sustained release, and toxicity reduction of the formulation. With Do-Coop's technology, pharmaceutical companies will achieve new and extended IP, an enhanced pipeline, significant cost reduction, and faster time to market by allowing researchers to use the same delivery system from in vitro to in vivo research, avoiding a key factor in late-stage failure. Biotech companies can benefit from enhanced protein stability, cell growth clonability and secretion, by using Neowater((R))-based media. Do-Coop's business model is licensing Neowater((R)) for various applications via technology transfer.
This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2008 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.
For more information, please click here
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016